All articles by

Health Canada approves TerSera’s Zoladex LA for ER+ breast cancer

Health Canada has approved TerSera’s supplemental new drug submission (sNDA) to use Zoladex LA 10.8mg in ER+ early breast cancer patients with a high risk of women in pre- and perimenopausal phase with recurrence or advanced breast cancer

Biotheryx announces US FDA clearance of IND application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6

FDA clears Azurity’s Myhibbin as oral suspension for organ transplant recipients

AstraZeneca completes equity investment agreement with Cellectis

Bayer Pharmaceuticals takes full ownership of Bayer Zydus Pharma